139 related articles for article (PubMed ID: 17111253)
21. Varying levels of family history of breast cancer in relation to mammographic breast density (United States).
Crest AB; Aiello EJ; Anderson ML; Buist DS
Cancer Causes Control; 2006 Aug; 17(6):843-50. PubMed ID: 16783612
[TBL] [Abstract][Full Text] [Related]
22. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
Garwood ER; Kumar AS; Shim V
Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
[TBL] [Abstract][Full Text] [Related]
23. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
[TBL] [Abstract][Full Text] [Related]
24. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.
Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ
Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236
[TBL] [Abstract][Full Text] [Related]
25. The basal and TRH stimulated levels of prolactin in low risk climacteric patients with increased breast density: a matched pair case control trial.
Soysal S; Soysal ME; Karabulut N; Gul N; Gezgin T
Maturitas; 2006 May; 54(2):103-9. PubMed ID: 16530361
[TBL] [Abstract][Full Text] [Related]
26. Effects of hormone replacement therapy on mammographic findings.
Bülbül NH; Ozden S; Dayicioglu V
Arch Gynecol Obstet; 2003 Apr; 268(1):5-8. PubMed ID: 12673467
[TBL] [Abstract][Full Text] [Related]
27. Postmenopausal hormone therapy and risk of breast cancer.
Chen FP
Chang Gung Med J; 2009; 32(2):140-7. PubMed ID: 19403003
[TBL] [Abstract][Full Text] [Related]
28. Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women.
Sprague BL; Trentham-Dietz A; Terry MB; Nichols HB; Bersch AJ; Buist DS
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3128-33. PubMed ID: 18990754
[TBL] [Abstract][Full Text] [Related]
29. Hormone therapy and breast cancer risk.
Foidart JM; Desreux J; Pintiaux A; Gompel A
Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
[TBL] [Abstract][Full Text] [Related]
30. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
Kerlikowske K; Cook AJ; Buist DS; Cummings SR; Vachon C; Vacek P; Miglioretti DL
J Clin Oncol; 2010 Aug; 28(24):3830-7. PubMed ID: 20644098
[TBL] [Abstract][Full Text] [Related]
32. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
[TBL] [Abstract][Full Text] [Related]
33. Breast density in women with premature ovarian failure using hormone therapy.
Benetti-Pinto CL; Soares PM; Magna LA; Petta CA; Dos Santos CC
Gynecol Endocrinol; 2008 Jan; 24(1):40-3. PubMed ID: 18224543
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
[TBL] [Abstract][Full Text] [Related]
35. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
[TBL] [Abstract][Full Text] [Related]
36. Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort.
Ringa V; Fritel X; Varnoux N; Zins M; Piault S; Quelen C
Maturitas; 2007 Nov; 58(3):216-25. PubMed ID: 17919857
[TBL] [Abstract][Full Text] [Related]
37. [Effect of hormone replacement therapy on the mammographic density of the female breast].
Egyed Z; Péntek Z; Magyar Z
Magy Onkol; 2005; 49(4):319-21, 323-5. PubMed ID: 16518476
[TBL] [Abstract][Full Text] [Related]
38. The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density.
von Schoultz B
Maturitas; 2004 Sep; 49(1):S16-21. PubMed ID: 15351103
[TBL] [Abstract][Full Text] [Related]
39. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
Windler E; Zyriax BC; Eidenmüller B; Boeing H
Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
[TBL] [Abstract][Full Text] [Related]
40. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study.
Kelemen LE; Pankratz VS; Sellers TA; Brandt KR; Wang A; Janney C; Fredericksen ZS; Cerhan JR; Vachon CM
Am J Epidemiol; 2008 May; 167(9):1027-36. PubMed ID: 18385204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
